ArticleTherapeutics and clinical risk management2025

Risk of Serious Immune-Related Adverse Events with Various PD1 and PD-L1 Inhibitors: A Single-Institution, Real-Life, Comparative Study.

Tiphaine Boucheron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.